PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC
Clinical trial NCT04284202 · UNKNOWN
Trial details
- NCT number
- NCT04284202
- Sponsor
- The Affiliated Hospital of Qingdao University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-01
- Primary completion
- 2020-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.